All In Biotech

Drug Trial Radar · NCT01085136

LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib

Phase III Randomized Trial of BIBW 2992 Plus Weekly Paclitaxel Versus Investigator's Choice of Chemotherapy Following BIBW 2992 Monotherapy in Non-small Cell Lung Cancer Patients Failing Previous Erlotinib or Gefitinib Treatment (LUX Lung 5)

Last checked: Nov 19, 2026Latest source record: Apr 4, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,154 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,154

Actual

Start

Feb 2010

Primary completion

Oct 2013

Study completion Jan 2016

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Mar 11, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this randomized, open-label, active-controlled, multi-center trial is to determine the efficacy of BIBW 2992 given as an add-on to chemotherapy in patients with NSCLC Stage IIIb or IV progressing after BIBW 2992 monotherapy compared to chemotherapy alone in this patient population. Patients on both treatment arms will receive best supportive care in addition to study treatment. Patients enrolled into the trial will be treated and followed until death or lost to follow-up. Additional information on the health-related quality of life (HRQOL) will be collected.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

  • Investigator´s choice of chemotherapyDrug

    BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy

  • BIBW 2992Drug

    BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (Part B)Time frame: From randomization until disease progression or death; Up to 32 months

Locations

97 sites in 23 countries. Site status is shown where the registry gives one.

  • Boehringer Ingelheim Investigational Site

    Buenos Aires, Argentina

  • Boehringer Ingelheim Investigational Site

    Kingswood, New South Wales, Australia

  • Boehringer Ingelheim Investigational Site

    South Brisbane, Queensland, Australia

  • Boehringer Ingelheim Investigational Site

    Box Hill, Victoria, Australia

  • Boehringer Ingelheim Investigational Site

    Fitzroy, Victoria, Australia

  • Boehringer Ingelheim Investigational Site

    Wodonga, Victoria, Australia

  • Boehringer Ingelheim Investigational Site

    Salzburg, Austria

  • Boehringer Ingelheim Investigational Site

    Aalst, Belgium

  • Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • Boehringer Ingelheim Investigational Site

    Duffel, Belgium

  • Boehringer Ingelheim Investigational Site

    La Louvière, Belgium

  • Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • Boehringer Ingelheim Investigational Site

    Middelheim, Belgium

  • Boehringer Ingelheim Investigational Site

    Ottignies, Belgium

  • Boehringer Ingelheim Investigational Site

    Porto Alegre, Brazil

  • Boehringer Ingelheim Investigational Site

    Beijing, China

  • Boehringer Ingelheim Investigational Site

    Changchun, China

  • Boehringer Ingelheim Investigational Site

    Chengdu, China

  • Boehringer Ingelheim Investigational Site

    Fuzhou, China

  • Boehringer Ingelheim Investigational Site

    Guangzhou, China

  • Boehringer Ingelheim Investigational Site

    Hangzhou, China

  • Boehringer Ingelheim Investigational Site

    Nanjing, China

  • Boehringer Ingelheim Investigational Site

    Shanghai, China

  • Boehringer Ingelheim Investigational Site

    Helsinki, Finland

  • Boehringer Ingelheim Investigational Site

    Bayonne, France

  • Boehringer Ingelheim Investigational Site

    Caen, France

  • Boehringer Ingelheim Investigational Site

    Dijon, France

  • Boehringer Ingelheim Investigational Site

    La Tronche, France

  • Boehringer Ingelheim Investigational Site

    Lyon, France

  • Boehringer Ingelheim Investigational Site

    Paris, France

  • Boehringer Ingelheim Investigational Site

    Saint-Herblain, France

  • Boehringer Ingelheim Investigational Site

    Villejuif, France

  • Boehringer Ingelheim Investigational Site

    Berlin, Germany

  • Boehringer Ingelheim Investigational Site

    Essen, Germany

  • Boehringer Ingelheim Investigational Site

    Esslingen am Neckar, Germany

  • Boehringer Ingelheim Investigational Site

    Gauting, Germany

  • Boehringer Ingelheim Investigational Site

    Hamburg, Germany

  • Boehringer Ingelheim Investigational Site

    Hanover, Germany

  • Boehringer Ingelheim Investigational Site

    Heidelberg, Germany

  • Boehringer Ingelheim Investigational Site

    Mainz, Germany

Showing 40 of 97 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.